We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has decided certain patients will be able to take Novartis’ Zelnorm, despite the fact that Novartis withdrew the drug from the market at the agency’s request in March due to an increased risk of cardiovascular events.